Analysis of different parameters of an optimized prolonged release formulation obtained by five processes

1991 ◽  
pp. 57-70
Keyword(s):  
Prolonged Release ◽  
Release Formulation

Galantamine Prolonged-Release Formulation in the Treatment of Mild to Moderate Alzheimer’s Disease

2005 ◽  
Vol 20 (2-3) ◽  
pp. 120-132 ◽  
Author(s):  
Henry Brodaty ◽  
Jody Corey-Bloom ◽  
Felix C.V. Potocnik ◽  
Luc Truyen ◽  
Michael Gold ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Prolonged Release ◽  
Release Formulation

scholarly journals Effect of a Prolonged-Release Formulation of N-Methionyl Bovine Somatotropin (Sometribove) on Milk Composition

1992 ◽  
Vol 75 (7) ◽  
pp. 1775-1793 ◽  
Author(s):  
D.M. Barbano ◽  
J.M. Lynch ◽  
D.E. Bauman ◽  
G.F. Hartnell ◽  
R.L. Hintz ◽  
...  
Keyword(s):  
Milk Composition ◽  
Bovine Somatotropin ◽  
Prolonged Release ◽  
Release Formulation

scholarly journals Development and Optimization of a Novel Prolonged Release Formulation to Resist Alcohol-Induced Dose Dumping

2015 ◽  
Vol 17 (2) ◽  
pp. 350-357 ◽  
Author(s):  
Chaitanya Yogananda Gujjar ◽  
Balaramesha Chary Rallabandi ◽  
Ramesh Gannu ◽  
Vallabh Subashrao Deulkar
Keyword(s):  
Prolonged Release ◽  
Release Formulation

scholarly journals Effects of a Prolonged-Release Formulation of Sometribove (n-Methionyl Bovine Somatotropin) on Jersey Cows

1992 ◽  
Vol 75 (12) ◽  
pp. 3416-3431 ◽  
Author(s):  
A.N. Pell ◽  
D.S. Tsang ◽  
B.A. Howlett ◽  
M.T. Huyler ◽  
V.K. Meserole ◽  
...  
Keyword(s):  
Bovine Somatotropin ◽  
Prolonged Release ◽  
Release Formulation ◽  
Jersey Cows

scholarly journals Modern approaches to drug treatment for vestibular vertigo

2021 ◽  
Vol 13 (1) ◽  
pp. 101-106
Author(s):  
M. V. Zamergrad ◽  
S. V. Morozova
Keyword(s):  
Patient Adherence ◽  
Beta Blockers ◽  
Antiviral Agents ◽  
Symptomatic Treatment ◽  
New Drugs ◽  
Dopamine Antagonists ◽  
Prolonged Release ◽  
Release Formulation ◽  
Hunt Syndrome ◽  
Vestibular Vertigo

In recent years, some progress has been achieved in elaborating the algorithms and standards for the treatment of many conditions accompanied by vertigo. The current possibilities of treating vestibular vertigo consist of a gradually expanding arsenal of symptomatic and pathogenetic drugs. Among the drugs used for the symptomatic treatment of vestibular vertigo, there are vestibular suppressants (antihistamines, benzodiazepines, and calcium antagonists) and antiemetics (dopamine antagonists and serotonin 5-HT3 receptor antagonists). The paper discusses the possibilities of using betahistine and vitamin D as pathogenetic agents for recurrent benign paroxysmal positional vertigo; diuretics, betahistine (including the new prolonged release formulation Betaserc® Long), glucocorticoids, and gentamicin for Meniere's disease; triptans, beta-blockers, tricyclic antidepressants, and anticonvulsants for vestibular migraine; glucocorticoids, antiviral agents, and drugs that accelerate vestibular compensation for acute unilateral peripheral vestibulopathy (vestibular neuritis and Ramsey Hunt syndrome).The emergence of new drugs, as well as the design of new dosage forms that enhance patient adherence to the prescribed treatment, can improve quality of life in patients suffering from diseases that have recently led to long-term disability or even incapacitation.

Sign in / Sign up

Export Citation Format

Share Document